Choosing a partner for
HPAPI success
Adam Kujath , senior director of technical operations at Sterling Pharma Solutions , looks at the value of using a CDMO in the manufacture of HPAPIs
Kujath - Companies making HPAPIs need far more than just the facilities
More than a quarter of all drugs today involve some kind of highly potent compound , whether that is an intermediate or the API itself . 1 Demand for HPAPIs is being driven by multiple factors , notably the growth in the market for certain targeted therapeutics and the increasing complexity of these treatments . A recent report projected that the global HPAPI market will grow at a CAGR of 8.7 % between 2019 and 2026 – faster than the small molecule sector overall . There is also likely to be a significant increase in value , with the market worth $ 32.2 billion by 2026 . 2 Drivers behind this include advances in drug design : structureactivity relationships used in in silico modelling ; toxicogenomics , which analyses gene expressions to predict pharmacological effect ; and computational biology , which uses computer and mathematical models to predict activity based on the API active site . Because these techniques yield highly specific , very targeted therapies , they can be applied at a lower dose .